Tarsus Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Tarsus Pharmaceuticals

13/03/2023 21:05

* Tarsus Pharmaceuticals Inc  TARS.OQ  reported a quarterly
adjusted loss of 49 cents​​ per share for the quarter ended in
December. The mean expectation of six analysts for the quarter
was for a loss of 69 cents per share.
    * Revenue rose 2,858.6% to $10.00 million from a year ago;
analysts expected $10.00 million. 
    * Tarsus Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 49 cents​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * Tarsus Pharmaceuticals Inc shares had fallen by 2.7% this
quarter.
    * The company reported a quarterly loss of $13.6 million.
    * Wall Street's median 12-month price target for Tarsus
Pharmaceuticals Inc is $43.00 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 7 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 13 at 09:05 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.69          -0.49          Beat
 Sep. 30 2022      -0.97          -0.84          Beat
 Jun. 30 2022      -0.59          -0.24          Beat
 Mar. 31 2022      -0.92          -0.98          Missed